Navigation Links
Lymphoma Research Foundation announces recipients of CLL/SLL Research Initiative grants
Date:10/28/2009

New York, NY The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are the same disease with slightly different manifestations. Where the cancerous cells gather determines whether it is called CLL or SLL. When the cancer cells are primarily found in the lymph nodes, lima bean shaped structures of the lymphatic system, an essential part of the body's immune system, it is called SLL. When most of the cancer cells are in the bloodstream and the bone marrow, it is called CLL.

John Balan, founder of the CLL Information Group with membership of approximately 1000 patients and caregivers, expressed the group's delight with these two awards. "We have a great deal of respect for the work that Drs. Kipps and Frank have been doing with CLL. These two awards will only augment what they have already done and add to the arsenal of treatments available to patients."

The purpose of Dr. Frank's, A Clinical Trial of STAT3 Inhibition in Patients with CLL, will be to evaluate the benefits of targeted therapy for CLL/SLL patients. Through prior research, Dr. Frank and his team found that CLL/SLL cells are characterized by an abnormality in a protein called STAT3, which regulates genes controlling the abnormal proliferation of lymphocytes in patients with this disease. They further identified a drug that inhibits STAT3, and, with the two-year $300,000 grant from LRF, Dr. Frank will carry out a clinical trial to test its safety and effectiveness in CLL/SLL patients. This is Dr. Frank's second LRF grant supporting his efforts to discover more effective CLL/SLL therapeutics.

Dr. Kipps' "Gene-Chemoimmunotherapy for Intractable Chronic Lymphocytic Leukemia" will focus on developing a treatment option for CLL/SLL patients with refractory disease who have limited treatment options. Dr. Kipps and his team have found that gene-immune therapy can render drug-resistant cells sensitive to chemotherapy. With this two-year $200,000 grant, Dr. Kipps will examine the mechanism(s) of drug-resistant disease and will pursue a clinical trial examining the use of gene-immune therapy to improve the capacity of patients with CLL/SLL refractory disease to respond to chemotherapy. Dr. Kipps is a member of the Foundation's Scientific Advisory Board.


'/>"/>

Contact: Marion F. Swan
mswan@lymphoma.org
347-920-6680
Lymphoma Research Foundation
Source:Eurekalert  

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. January 1 Looms Large for Lymphoma Patients
5. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
6. Possible Cure for Rare Lymphoma Reported
7. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
8. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
9. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
10. Lymphoma drug used to treat skin disorders
11. Firefly genes allow testing of new therapy against lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lymphoma Research Foundation announces recipients of CLL/SLL Research Initiative grants
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy ... be found at 9618 Huebner Road. The clinic is the group’s 7th location in ... and Dr. Ali Higgins, PT, will provide care from the clinic, which opened March ...
(Date:3/24/2017)... ... March 24, 2017 , ... In ... innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 ... – with nearly 2,000 consumers (and counting) already backing the campaign. , ...
(Date:3/24/2017)... , ... March 24, 2017 , ... The law firm ... Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea has joined the ... for the firm, will concentrate her practice in elder law, Medicaid planning and applications, ...
(Date:3/24/2017)... ... 2017 , ... Judy Buchanan, co-owner of Serenity Natural Health ... says, “I am passionate about sharing Reiki as a holistic, complementary therapy with ... time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical Reiki™ ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... inspiring stories about real people of God in congregations across the United States. ... a Presbyterian minister ordained in 1964 who has served congregations in seven states ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 ... 2016-2022 Among the various wound care products type, the advanced ... in 2015. Among the various applications, surgical wound segment held the largest ...
(Date:3/24/2017)... SHANGHAI , March 24, 2017 /PRNewswire/ ... organization providing high-quality and cost-effective drug development ... the pharmaceutical and biotechnology industry, announced today ... ShangPharma will be consolidating the ... Organizations (CMO) under Shanghai ChemPartner. These entities ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 ... market of deep learning solutions within the healthcare domain. Primarily driven ... a novel solution to generate relevant insights from medical data. ...
Breaking Medicine Technology: